Citations

Clear

350 citation(s) found for "Stevens, V".

Impact of Affect on Lung Transplant Candidate Outcomes
Pennington, Kelly M. , Benzo, Roberto P. , Schneekloth, Terry D. , Budev, Marie , Chandrashekaran, Satish, Erasmus, D , Levine, Deborah J. , Thompson, Karin L., Novotny, Paul J. , Kennedy, Cassie C. , Erasmus, David B, Thompson, Karin, Stevens, Elizabeth, Kennedy, Cassie C , Lease, Erika D. , Stevens, Elizabeth

Mayo Clinic

Progress in Transplantation | December 16, 2019 | Volume: 30 | Issue: 1 | Pages: 13-21

10.1177/1526924819892921 | PMID 31838950 Get It

Background: We examined the association of adult lung transplant candidates’ self-reported affect with transplant-related outcomes, evaluating whether a positive (vs negative) frame of mind might be protective. Method: Consenting waitlisted candidates from 6 centers completed the questionnaires including the Positive and Negative Affect Schedule annually and posttransplant. Univariate logistic regression analysis was performed to determine the association of baseline affect with outcomes of death or delisting. Models were subsequently adjusted for age, marital status, and education. Results: Questionnaires were completed by 169 candidates (77.9% participation). Mean positive affect, negative affect, and positive-to-negative affect ratio (positivity ratio) were similar to expected norms. The scores of the questionnaire did not change significantly over time. Fifteen (8.9%) waitlisted participants died. Candidates who died while waiting had lower positivity ratios compared to those who survived (1.82 vs 2.45; P = .02). A more negative affect was associated with increased death on the waiting list (adjusted odds ratio [OR] 1.10; P = .021). Conversely, a higher positivity ratio was associated with decreased death while waiting (adjusted OR: 0.45; P = .027). Conclusion: Negative affect may represent a novel risk factor for death on the waitlist. Enhancing positive affect may represent a useful target for psychological optimization in lung transplant candidates.
Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure
Singer, Bridger, Stevens, Ryan W. , Westley, Benjamin , Nicolau, David P. , Stevens, Ryan W

Mayo Clinic

American Journal of Health-System Pharmacy | November 7, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajhp/zxz258 | PMID 31697345 Get It

Abstract Purpose A case of vancomycin enzyme immunoassay (EIA) interference confirmed by high-performance liquid chromatography (HPLC) is described. Summary Therapeutic drug monitoring is standard of practice in vancomycin dosing and monitoring in order to maximize the pharmacodynamic effects and minimize toxicity. After a 52-year-old woman received 5 doses of vancomycin, serum concentrations continued to rise for several days in the absence of ongoing vancomycin administration. Despite persistently elevated vancomycin concentrations, the patient clinically deteriorated and required treatment with an alternative agent. Subsequently, serum concentrations were processed via HPLC and analyzed for percent protein binding. Confirmatory analysis revealed substantially lower concentrations by HPLC than were obtained by EIA and an abnormal elevation in protein binding. After discharge from the index admission, the patient returned 11 months later and had a dectectable vancomycin concentration by EIA prior to receipt of vancomycin. HPLC analysis confirmed the true concentration was undetectable. Though the exact interfering substance was not identified, the above discrepancy in concentrations between the two assay methods indicates the presence of assay interference, and adds to the available literature suggesting similar occurrences. This case is particularly troubling given that the level of interference was not such that it would lead a clinician to immediately suspect interference, and the patient experienced treatment failure. Conclusion Falsely elevated values for serum vancomycin concentration, measured by EIA, contributed to treatment failure in a patient. The substance presumably responsible for EIA interferences was not identified.
Infectious Mononucleosis: the Prognostic Significance of Various Changes of the Blood Leukocytes
Stevens, John E., Bayrd, Edwin D., Heck, Frank J., STEVENS, JOHN E.

Mayo Clinic

Blood | October 12, 2019 | Volume: 7 | Issue: 1 | Pages: 31-36

10.1182/blood.v7.1.31.31 Get It

Abstract Peripheral blood smears were studied in 25 selected cases of infectious mononucleosis. In 7 the onset was acute and the course severe, in 6 the onset was acute and the course mild, in 6 the onset was gradual and the course severe, and in 6 the onset was gradual and the course mild. The predominance of any of the various types of lymphocytes of infectious mononucleosis was not noted to bear any relationship to the clinical course, although type III lymphocytes and granulocytic immaturity may be more frequently seen when the onset is acute. When toxic changes are present in the granulocytes, the clinical course is likely to be severe.
Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
Jones, Jeffrey A. , Mato, Anthony R. , Österborg, Anders , Thirman, Michael J. , Furman, Richard R. , İlhan, Osman , Keating, Michael J. , Call, Timothy G. , Brown, Jennifer R. , Stevens-Brogan, Michelle, Li, Yunfeng , Fardis, Maria, Clow, Fong, James, Danelle F. , Chu, Alvina D., O’Brien, Susan , Coutré, Steven , Hillmen, Peter , Tam, Constantine S. , Siddiqi, Tanya , Hallek, Michael , Stilgenbauer, Stephan

Mayo Clinic

Blood | October 11, 2019 | Volume: 124 | Issue: 21 | Pages: 327-327

10.1182/blood.v124.21.327.327 Get It

Abstract Background: Patients with chronic lymphocytic leukemia (CLL) with deletion of the short arm of chromosome 17 (del 17p) follow an aggressive clinical course and demonstrate a median survival of less than 2 years in the relapsed/refractory (R/R) setting. Ibrutinib (ImbruvicaTM), a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, has been approved for previously treated patients with CLL and for patients with del 17p CLL. We report results from the primary analysis of the Phase II RESONATETM-17 (PCYC-1117-CA) study, designed to evaluate the efficacy and safety of single-agent ibrutinib for treatment of patients with R/R del 17p CLL or small lymphocytic leukemia (SLL). Methods: Patients with del 17p CLL or SLL who failed at least one therapy were enrolled to receive 420 mg oral ibrutinib once daily until progression. All patients receiving at least one dose of ibrutinib were included in the analysis. The primary endpoint was overall response rate (ORR) per an independent review committee (IRC). Other endpoints included duration of response (DOR), progression-free survival (PFS), and safety of ibrutinib. Results: Among 144 treated patients (137 with CLL, 7 with SLL), the median age was 64 (48% 65 years or older) and all had del 17p. Baseline characteristics included 63% of patients with Rai Stage III or IV disease, 49% with bulky lymphadenopathy of at least 5 cm, and 10% with lymphadenopathy of least 10 cm. The median baseline absolute lymphocyte count (ALC) was 32.9 x 109/L with 57% of patients with a baseline ALC at least 25.0 x 109/L. Baseline beta-2 microglobulin levels were at least 3.5 mg/L in 78% of patients (range 1.8-19.8 mg/L), and lactate dehydrogenase levels were at least 350 U/L in 24% of patients (range 127-1979 U/L). A median of 2 prior therapies (range 1-7) was reported. Investigator-assessed ORR was 82.6% including 17.4% partial response with lymphocytosis (PR-L). Complete response (CR)/complete response with incomplete bone marrow recovery (CRi) were reported in 3 patients. IRC-assessed ORR is pending. At a median follow up of 13.0 months (range 0.5-16.7 months), the median PFS (Figure 1) and DOR by investigator determination had not been reached. At 12 months, 79.3% were alive and progression-free, and 88.3% of responders were progression-free. Progressive disease was reported in 20 patients (13.9%). Richter transformation was reported in 11 of these patients (7.6%), 7 of the cases occurring within the first 24 weeks of treatment. Prolymphocytic leukemia was reported in 1 patient. The most frequently reported adverse events (AE) of any grade were diarrhea (36%; 2% Grade 3-4), fatigue (30%; 1% Grade 3-4), cough (24%; 1% Grade 3-4), and arthralgia (22%; 1% Grade 3-4). Atrial fibrillation of any grade was reported in 11 patients (7.6%; 3.5% Grade 3-4). Seven patients reported basal or squamous cell skin cancer and 1 patient had plasma cell myeloma. Most frequently reported Grade 3-4 AEs were neutropenia (14%), anemia (8%), pneumonia (8%), and hypertension (8%). Major hemorrhage was reported in 7 patients (4.9%, all Grade 2 or 3). Study treatment was discontinued in 16 patients (11.1%) due to AEs with 8 eventually having fatal events (pneumonia, sepsis, myocardial or renal infarction, health deterioration). At the time of data cut, the median treatment duration was 11.1 months, and 101 of 144 patients (70%) continued treatment with ibrutinib. Conclusions: In the largest prospective trial dedicated to the study of del 17p CLL/SLL, ibrutinib demonstrated marked efficacy in terms of ORR, DOR, and PFS, with a favorable risk-benefit profile. At a median follow up of 13 months, the median DOR had not yet been reached; 79.3% of patients remained progression-free at 12 months, consistent with efficacy observed in earlier studies (Byrd, NEJM 2013;369:32-42). The PFS in this previously treated population compares favorably to that of treatment-naïve del 17p CLL patients receiving fludarabine, cyclophosphamide, and rituximab (FCR) (Hallek, Lancet 2010;376:1164-74) or alemtuzumab (Hillmen, J Clin Oncol 2007;10:5616-23) with median PFS of 11 months. The AEs are consistent with those previously reported for ibrutinib (Byrd, NEJM 2014;371:213-23). These results support ibrutinib as an effective therapy for patients with del 17p CLL/SLL. Figure 1 Figure 1. Disclosures O'Brien: Amgen, Celgene, GSK: Consultancy; CLL Global Research Foundation: Membership on an entity's Board of Directors or advisory committees; Emergent, Genentech, Gilead, Infinity, Pharmacyclics, Spectrum: Consultancy, Research Funding; MorphoSys, Acerta, TG Therapeutics: Research Funding. Jones:Pharmacyclics: Consultancy, Research Funding. Coutre:Janssen, Pharmacyclics: Honoraria, Research Funding. Mato:Pharamcyclics, Genentech, Celegene, Millennium : Speakers Bureau. Hillmen:Pharmacyclics, Janssen, Gilead, Roche: Honoraria, Research Funding. Tam:Pharmacyclics and Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Siddiqi:Janssen: Speakers Bureau. Furman:Pharmacyclics: Consultancy, Speakers Bureau. Brown:Sanofi, Onyx, Vertex, Novartis, Boehringer, GSK, Roche/Genentech, Emergent, Morphosys, Celgene, Janssen, Pharmacyclics, Gilead: Consultancy. Stevens-Brogan:Pharmacyclics: Employment. Li:Pharmacyclics: Employment. Fardis:Pharmacyclics: Employment. Clow:Pharmacyclics: Employment. James:Pharmacyclics: Employment. Chu:Pharmacyclics: Employment, Equity Ownership. Hallek:Janssen, Pharmacyclics: Consultancy, Research Funding. Stilgenbauer:Pharmacyclics, Janssen Cilag: Consultancy, Honoraria, Research Funding.
Genetic Susceptibility Markers of Multiple Myeloma in African-Americans
Rand, Kristin A. , Song, Chi , Hwang, Amie E. , Huff, Carol Ann , Bernal‐Mizrachi, Leon , Sheng, Xin , Graff, John J., Zimmerman, Todd M., Pawlish, Karen , Stram, Alexander , Strom, Sara S., Terebelo, Howard R. , Stanford, Janet L. , Goodman, Phyllis J. , Berndt, Sonja I. , Carpten, John, Hennis, Anselm , Chu, Lisa W., Driver, W. Ryan, Leske, M. Christina, Murphy, Adam B. , Stevens, Victoria L. , Pettaway, Curtis A. , Witte, John S. , Zheng, Siqun L., Xu, Jianfeng , Munshi, Nikhil C. , Hsing, Ann W. , Mehta, Jayesh, Signorello, Lisa B., Nemesure, Barbara , Mohrbacher, Ann, Janakiraman, Nalini, Blot, William J. , Henderson, Brian E., Kolonel, Laurence N. , Zonder, Jeffrey A. , Haiman, Christopher, Tomasson, Michael H. , Ailawadhi, Sikander , Berg, David Van Den , Conti, David V. , Peters, Edward , Singhal, Seema , Bock, Cathryn Hufford , Colditz, Graham A. , Stram, Alex , Rybicki, Benjamin A. , Kittles, Rick A. , Casey, Graham , Klein, Eric A. , John, Esther M. , Neslund-Dudas, Christine M , Zheng, Wei , Wu, Szu‐Yuan , Ingles, Sue A. , Chanock, Stephen Jacob , Anderson, Kenneth C. , Chiu, Brian C.‐H. , Orlowski, Robert Z. , Lonial, Sagar , Stram, Daniel O. , Cozen, Wendy

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 2030-2030

10.1182/blood.v124.21.2030.2030 Get It

Abstract Multiple myeloma (MM) is 2-3 times more common among African-Americans compared to non-Hispanic whites. The 2-3-fold increased risk among family members of cases suggests a genetic contribution to risk. Genome-wide association studies (GWAS) in populations of European ancestry have identified seven novel risk loci at 2p23.3 (rs6746082), 3q26.2 (rs10936599), 3p22.1 (rs1052501), 6p21.32 (rs2285803), 7p15.3 (rs4487645), 17p11.2 (rs4273077) and 22q13.1 (rs877529) (Broderick, et al. Nat Genet, 2011, Chubb, et al. Nat Genet, 2013), three of which were replicated in another European series (Martino et al., Br J Haematol, 2012). Here we examined the index signals and conducted fine-mapping for each locus in a case-control study of 1,049 multiple myeloma cases and 7,084 controls of African ancestry to identify better markers of risk and novel independent loci in seven previously reported regions in this high risk population. Incident cases were recruited from 10 clinical centers and SEER cancer registries from 2011 to 2013 and genotyped using the Illumina HumanCore GWAS array. Control data were obtained from previous genome-wide studies of breast and prostate cancer, genotyped using the Illumina 1M-Duo in 4425 male controls from the African Ancestry Prostate Cancer Consortium (consisting of 14 independent studies) and 2632 female controls from a breast cancer GWAS of African-American women (consisting of 9 independent studies). Imputation to 1000 Genomes (March 2012 release) was conducted for regions around six of the previously identified single nucleotide polymorphisms [SNPs] (the HLA region harboring rs2285803 is still being imputed, results will be presented). A case-control analysis of SNPs/indels >1% frequency within 250 kb of each index variant was conducted using unconditional multivariable logistic regression adjusting for age, sex and five leading principal components. Region-specific alpha levels were determined through permutation tests. The minimum alpha level across the six regions was α=0.002. All previously reported risk variants were common in African-Americans (minor allele frequency [MAF] >0.05). For five of the six SNPs, we had ≥94% power to detect the same effect observed in non-Hispanic whites, and 64% power for the less common variant rs10936599 (MAF=0.07). We observed directionally consistent effects (odds ratio [OR]>1) for the six risk variants tested, with three replicating at p≤0.05 (7p15.3, p=1.4x10-7; 17p11.2, p=0.05; 22q13.1, p=0.02). For three of the six regions, we observed better markers of risk in African-Americans that were correlated with the index SNP in Europeans (7p15.3, rs56333627, p=1.5x10-5, r2=0.89; 17p11.2, rs34562254, p=2.9x10-3, r2=0.90; 22q13.1, rs2092410, p=1.1x10-4 r2=.71). The missense variant identified in the 17p11.2 region (rs34562254, Pro251Leu) is located in TNFRSF13B, which encodes the protein TACI, a B cell surface receptor which plays a role in B cell maturation, apoptosis and antibody production by inducing activation of transcription factors including NFAT and NFκβ. In addition, there is evidence suggesting that TACI is involved in MM pathogenesis. Our results demonstrate that many of the risk loci for MM found in European ancestry populations are also risk loci in men and women of African ancestry and that by fine-mapping, we are able to identify variants that better capture risk in populations of African ancestry. Disclosures Terebelo: Celgene Corp: Membership on an entity's Board of Directors or advisory committees. Lonial:Millennium: The Takeda Oncology Company: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Onyx Pharmaceuticals: Consultancy, Research Funding.
Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug‐Resistant Pseudomonas aeruginosa : A Case Report
Stevens, Ryan W. , Clancy, Megan, Stevens, Ryan W

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 24, 2019 | Volume: 39 | Issue: 11 | Pages: 1113-1118

10.1002/phar.2334 | PMID 31550054 Get It

Multidrug‐resistant (MDR) Pseudomonas aeruginosa infections often represent a therapeutic challenge requiring utilization of older, more toxic antibiotics, or new agents with limited data. Once susceptibility to β‐lactam and fluoroquinolone antibiotics has been lost, other therapeutic options such as aminoglycoside or polymyxin antibiotics carry significant adverse effects such as nephrotoxicity, neurotoxicity, and ototoxicity. A novel cephalosporin, cefiderocol, lacks gram‐positive and anaerobic activity but offers broad coverage of gram‐negative bacteria, including P. aeruginosa . A unique catechol side chain gives it activity as a siderophore, thereby increasing bacterial uptake and decreasing efflux. Additionally, cefiderocol is stable against a wide array of β‐lactamases. Despite these promising characteristics, there are minimal data currently available in the literature detailing the use of cefiderocol in the treatment of MDR P. aeruginosa infections. We present a case of a 46‐year‐old man who developed an MDR P. aeruginosa intraabdominal infection where serious and life‐threatening toxicities to aminoglycosides and polymyxin antibiotics led to the utilization of cefiderocol on compassionate use approval. The isolate was susceptible to cefiderocol, and the patient was treated for 28 days of therapy. He demonstrated clinical and radiographic resolution of his infection and was discharged to home.
Parental Attitudes Towards Prenatal Genetic Testing For Sickle Cell Disease
Stevens, Evelyn , Patterson, Chavis A. , Tchume‐Johnson, Trudy, Antiel, Ryan M. , Flake, Alan W. , Smith‐Whitley, Kim , Barakat, Lamia P.

Mayo Clinic

Journal of Pediatric Hematology/Oncology | September 20, 2019 | Volume: 41 | Issue: 8 | Pages: 579-585

10.1097/mph.0000000000001592 | PMID 31568178 Get It

Uptake of prenatal genetic testing (PGT) is low among those with sickle cell disease (SCD). This study evaluated the association of knowledge and attitudes towards prenatal genetic counseling (PGC), awareness of posttesting intervention options and omission bias with attitudes towards PGT. In addition, we explored changes among knowledge, attitudes, and awareness of options following exposure to an educational, clinical vignette among parents of children with SCD. Parents (n=44) completed a questionnaire and an educational, clinical vignette presenting a detailed account of a pregnant woman with sickle cell trait seeking PGT and PGC was read to each participant.tTests, Spearman correlations, multivariable regressions, and moderation/mediation analyses were used. More positive attitudes towards PGC (P=0.01), lesser tendency of omission bias (P<0.01) and private insurance (P=0.04) were significant correlates of more positive attitudes towards PGT. Omission bias mediated the relationship of attitudes towards PGC and attitudes towards PGT (95% confidence interval: 0.13, 3.03). Awareness of options (P=0.02), knowledge of PGC (P=0.01) and knowledge of PGT (P=0.01) significantly improved after exposure to the clinical vignette. Patients and families with SCD can benefit from education about the importance of prenatal diagnosis to improve attitudes, address omission bias and promote more informed decisions of PGT.
Abstract 2426: Familial reinforcement and family history interact to influence knowledge about pancreatic cancer
Stevens, Maria , Mikhail, Dalia S., Hernández, Amanda Toledo, Fagan, Sarah , Chaffee, Kari G. , Petersen, Gloria M.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 2426-2426

10.1158/1538-7445.am2019-2426 Get It

Abstract Introduction: Family reinforcement (praise, reminders) may influence health behaviors and affect cancer knowledge, including risk factors. There has been insufficient research on the influence of familial factors in cancer prevention, especially for individuals with a family history of pancreatic cancer (PC). Objectives were to assess: 1) associations between family history of PC and familial reinforcement of cancer prevention with PC knowledge, and 2) interaction between family history of PC and familial reinforcement of cancer prevention on PC knowledge. Methods: A sample of 778 unaffected relatives with ≥1 affected first (FDR) or second degree relatives (SDR) were ascertained from Mayo Clinic’s Biospecimen Resource for Pancreas Research, a familial PC registry, along with 685 primary care controls. Participants with a personal history of cancer were excluded with the exception of non-melanoma skin cancer. Participants completed health/behavior questionnaires (June 2008 to June 2018). Items were summed to create factor scores for familial reinforcement of cancer prevention and PC knowledge. PC family history was categorized by number of relatives with PC: 1) none, 2) 1 FDR and/or ≥1 SDR, and 3) ≥2 FDRs. We employed linear models utilizing generalized estimating equations to assess the association between PC family history and familial reinforcement with PC knowledge, and the interaction based on PC family history, adjusting for age, sex, and education, and accounting for familial relatedness. Estimates of the linear coefficient β and 95% confidence intervals (CI) are reported, and p-values &lt; 0.05 were considered significant. Analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). Results: There was a significant association between PC family history and PC knowledge such that those with 1 FDR and/or ≥1 SDR (β=3.0; 95% CI: 2.5-3.4; p&lt;0.0001) or ≥2 FDRs (β=4.4; 95% CI: 3.7-5.0; p&lt;0.0001) with PC had increased PC knowledge after adjusting for age, sex, and education. There was a significant association between familial reinforcement and PC knowledge such that individuals with increased familial reinforcement (β=0.1; 95% CI: 0.03-0.12; p=0.0026) had higher PC knowledge after adjusting for pertinent covariates. The interaction between PC family history and familial reinforcement was significant such that increased familial reinforcement was associated with higher PC knowledge in individuals with ≥2 FDRs with PC compared to controls (β=0.2; 95% CI: 0.09-0.34; p=0.001); however, this relationship was not significant in individuals with 1 FDR and/or ≥1 SDR. Conclusions: Individuals with a stronger family history of PC may benefit from increased familial reinforcement of cancer prevention to enhance knowledge about PC. Further efforts should be targeted toward incorporating the family in cancer care to raise familial awareness about PC. Citation Format: Maria Stevens, Dalia Mikhail, Amanda Toledo Hernandez, Sarah Fagan, Kari Chaffee, Gloria M. Petersen. Familial reinforcement and family history interact to influence knowledge about pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2426.
Postoperative management of patients with spontaneous cerebrospinal fluid leak
Stevens, Shawn M. , Smith, Cody J. , Lawton, Michael

Mayo Clinic

Current Opinion in Otolaryngology & Head & Neck Surgery | July 30, 2019 | Volume: 27 | Issue: 5 | Pages: 361-368

10.1097/moo.0000000000000559 | PMID 31361610 Get It

Purpose of review To explore key management principles and outcomes following surgical intervention for spontaneous CSF leaks of the lateral skull base. Recent findings Outcomes following surgery for spontaneous CSF leaks of the lateral skull base depend on the surgical approach utilized. The approach reported most frequently in the literature is currently the middle fossa approach. Mean leak recurrence rates, regardless of approach, were approximately 6%. The lowest leak recurrence rates were associated with the combined middle cranial fossa-transmastoid approach. A multilayer closure was employed in all of the reviewed investigations, but the choice of reconstructive material did not significantly affect outcomes. Direct surgical complications rates, overall, were low at less than 2%. Meningitis, intracranial hemorrhage, and perioperative seizure activity were only rarely encountered. A concomitant diagnosis of idiopathic intracranial hypertension was found to be associated with increased rates of leak recurrence and sequential leak development at other skull base sites. Summary Postoperative management of patients with spontaneous CSF leaks of the lateral skull base has unique challenges. Observation of key treatment principles can lead to good outcomes and limit morbidity. A high index of suspicion should exist for concomitant idiopathic intracranial hypertension.
An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant
Whitwell, Jennifer L. , Stevens, Chase A., Martin, Peter R. , Botha, Hugo , Spychalla, Anthony J., Senjem, Matthew L. , Jack, Clifford R. , Ali, Farwa , Hassan, Anhar , Josephs, Keith A. , Strand, Edythe A. , Jack, Clifford R , Senjem, Matthew L , Botha, Hugo , Duffy, Joseph R. , Clark, Heather M. , Machulda, Mary M. , Utianski, Rene L. , Schwarz, Christopher G.

Mayo Clinic

Movement Disorders Clinical Practice | May 30, 2019 | Volume: 6 | Issue: 6 | Pages: 452-461

10.1002/mdc3.12796 | PMID 31392246 Get It

ABSTRACTBackgroundThe Movement Disorder Society clinical criteria for progressive supranuclear palsy (PSP) provide a framework for assessing the presence/severity of clinical symptoms and define a speech/language variant of PSP.ObjectivesTo evaluate the clinical criteria in a cohort of speech/language patients with longitudinal follow‐up.MethodsA total of 52 patients presenting with progressive apraxia of speech and/or agrammatic aphasia were followed longitudinally for up to 6 visits with clinical assessments and magnetic resonance imaging. We assessed oculomotor, postural instability, and akinesia diagnostic levels and determined whether patients met criteria for possible PSP‐speech/language or probable PSP at each visit. Kaplan‐Meier curves assessed time‐to‐event probabilities according to age. Statistical parametric mapping and midbrain volume were assessed according to disease progression.ResultsFew PSP symptoms were observed early in the disease, with oculomotor abnormalities and falls first observed 2 years after onset. Falls were more common than vertical supranuclear gaze palsy. Bradykinesia and rigidity commonly developed but axial was rarely greater than appendicular rigidity. During follow‐up, 54% met criteria for possible PSP‐speech/language, 38% for probable PSP‐Richardson's syndrome, and 38% for probable PSP‐parkinsonism, most commonly 6 to 6.9 years after onset. The probability of developing PSP was greater when onset was at an age older than 70 years. Patients who progressed to probable PSP had more parkinsonism and oculomotor impairment at baseline and greater midbrain atrophy when compared with those who did not develop probable PSP.ConclusionsSymptoms typical of PSP commonly develop in patients presenting with a progressive speech/language disorder. Older age appears to be an important prognostic factor in these patients.